INSTRUCTIONS What nurse practitioners should know about gene therapy
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 23. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is November 30, 2015.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223.
Your certificate is valid in all states.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
What nurse practitioners should know about gene therapy
General Purpose: To provide information about the progress of gene therapy clinical trials toward the management of patients with chronic disease. Learning Objectives: After reading this article and taking this test, you will be able to: 1. Recognize the progress that has been made in gene transfer therapy. 2. Identify elements of concern when gene therapy is applied to human patients.
1. The focus of gene therapy is to
a. sequence human genomes.
b. identify gene function and expression.
c. define nongenetic and genetic factor interactions.
d. treat disease through the use of genes.
2. Compared to viral gene therapy, nonviral gene therapy is associated with
a. secondary disease.
b. fatal immunologic responses.
c. increased adverse reactions.
d. increased safety profile.
3. Unlike germline human therapy, somatic gene therapy
a. alters precursor cells.
b. causes noninheritable effects.
c. alters the DNA in sperm.
d. is extremely controversial.
4. Which of these is a type of somatic gene therapy?
5. Trials using human factor IX transgene resulted in
a. maximum adverse reactions.
b. decreased bleeding.
c. increased platelet production.
d. resurgence of hemophilia B.
6. A recent animal study using silencing RNA therapy demonstrated
a. reduction of ovarian tumor proliferation.
b. tumor growth association with claudin 3.
c. decreased factor IX for patients with hemophilia B.
d. exacerbation of Bcl-2 proliferation in neuroblastoma tumors.
7. Which type of encoded protein is used in suicide gene therapy?
a. diphtheria toxin
d. nucleic acid
8. Which of these serves as a delivery vector for corrective gene therapy?
9. Which virus is often used for gene delivery because it invades the nuclei of cells without permanent alteration of the host genome?
b. anopheles B virus
10. Use of which of these vectors has improved the outcomes of nonviral therapy strategies?
11. Adenoviruses have been shown to
a. target and infect cells.
b. increase the chance of disruption of normal gene function.
c. decrease recipient safety.
d. deliver DNA that integrates into the host DNA.
12. Lentivirus is being studied as a vector for the treatment of diseases of the
13. Which of the following is not considered a potential danger of viral gene therapy?
a. undesired tissue mutations
b. infection of nontargeted organs
c. onset of systemic toxicities
d. dermal transfer to other subjects
14. Lipoplexes are administered
15. Lipoplexes commonly accumulate in the
c. adipose tissue.
16. In a trial that evaluated the effects of naked DNA to deliver hepatocyte growth factor to ischemic limbs, results included
a. decreased ankle-brachial index.
b. decreased angiogenesis.
c. increased wound healing.
d. increased limb pain.
17. Which of the following is used in conjunction with siRNA administration for more efficacious gene silencing?
a. photochemical internalization
d. naked DNA
18. Which of these produced a greater immunoprotective response when used as an intradermal delivery method of DNA and RNA?
a. jet injector
b. gene gun
c. dermal patch
d. hydrophyllic membrane